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Supplemental Figure 1. 11ɴ-HSD1 activity in control mice 11ɴ-HSD1 enzyme activity increased during healing and was 
inhibited by topical CBX (n=4-12, two-way ANOVA). Multiple comparisons: * = vs. baseline (day 0) in each treatment group 
(ƵŶŶĞƚ Ɛ͛ test), # = vs. VEH at each time-point (^ŝĚĂŬ Ɛ͛ test). Significance: * = p<0.05, ** = p<0.01, *** = p<0.001 
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Supplemental Figure 2. PCNA staining A) Representative PCNA immunostaining (n=4) and B) PCNA immunostaining 
quantification showing a trend towards decreased keratinocyte proliferation in CORT mice and improvement following 7 days 
topical CBX treatment (n=4, one-way ANOVA). Scale bar 50µm. 
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Supplemental Figure 3. Skin thickness in control mice A) Representative H+E staining following 7 days topical CBX treatment (n=4), B) 
Quantification of epidermal thickness (n=4, ^ƚƵĚĞŶƚ Ɛ͛ t-test), C) Quantification of keratinocyte density (n=4, ^ƚƵĚĞŶƚ Ɛ͛ t-test) and D) 
Quantification of dermal area (n=4, ^ƚƵĚĞŶƚ Ɛ͛ t-test). Scale bar 50µm. 
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Supplemental Figure 4. Epidermal barrier function in control mice 
A) Baseline trans-epidermal water loss (TEWL) following 7 days 
topical CBX treatment (n=12, ^ƚƵĚĞŶƚ Ɛ͛ t-test), B) Barrier integrity 
(n=12, ^ƚƵĚĞŶƚ Ɛ͛ t-test) and C) Barrier recovery relative to baseline 
TEWL (n=12,  two-way ANOVA). Multiple comparisons: * = vs. 2 
hour time-point in each treatment group (ƵŶŶĞƚ Ɛ͛ test), # = vs. 
VEH at each time-point (^ŝĚĂŬ Ɛ͛ test). Significance: * = p<0.05, ** = 
p<0.01, *** = p<0.001 
** *** 
0
1
2
3
4
5
6
7
8
9
VEH CBX
B
as
el
in
e 
TE
W
L 
(g/
h/
m
2 )
0
1
2
3
4
VEH CBX
B
ar
rie
r 
in
te
gr
ity
0
2
4
6
8
10
12
14
16
18
20
2 3 4 5 6 7 8
W
o
u
n
d 
a
re
a 
(A
.
U)
Day
VEH CBX
B A 
VEH 
CBX 
Supplemental Figure 5. Wound healing in control mice A) Representative wound appearance at day 9 (n=8) and B) 
Quantification of wound areas following topical CBX treatment (n=8-24, two-way ANOVA). Scale bar 12mm. Multiple 
comparisons for B: * = vs. day 4 in each treatment group (ƵŶŶĞƚ Ɛ͛ test). Significance: * = p<0.05, *** = p<0.001 
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